Cantor Fitzgerald’s virtual panel on “Emerging Targets in Development for Inflammatory Bowel Disease (IBD)”

  • April 27, 2021 - April 27, 2021
  • Virtual panel discussion

We are delighted to participate in a virtual panel discussion on “Emerging Targets in Development for Inflammatory Bowel Disease (IBD)”, which will be hosted by Cantor Fitzgerald Equity Research on April 27 at 10:00AM ET.
Invited speakers from Biomica: Dr. Elran Haber , CEO and Dr. Shiri Meshner, VP R&D.

Back to all News

Highlighted News About Biomica

May 23, 2024

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting REHOVOT, Israel, May 23, 2024. Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: […]

Read More